Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...

Vanguards VEA and VEU exchange trade funds both offer investors exposure to international markets and companies outside of ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

While Wegovy (semaglutide) sales more than doubled to DKK 19.87 billion ($2.78 billion) in the three-month period, that was ...

EU mid-market update: Trump adds Middle East tensions to macro picture as trade war keeps volatility high; Novo Nordisk rises ...

Recent price cuts by major insulin manufacturers may appear to address affordability challenges, but they primarily target older insulin drugs nearing patent expiration. This tactic, coupled with the ...

The markets are likely to show some reactions to Donald Trump’s trade war, sparked by the US imposing sweeping tariffs on ...

January jobs data is due on Friday. Plus, earnings from AMD, Alphabet, Chipotle, PayPal, Disney, Eli Lilly, Qualcomm, Amazon, ...